



STAY CURRENT with FDA-Approved Immunotherapy Treatments

2019-2020 ACI SERIES

From September 2019 through March 2020, the upcoming ACI series includes programs in the following cities*:

- Cleveland-**Sept. 5, 2019**
- Chicago-**Sept. 28, 2019**
- Boston-**Oct. 10, 2019**
- Buffalo, N.Y.-**Oct. 26, 2019**
- Philadelphia-**Nov. 12, 2019**
- San Francisco-**Nov. 14, 2019**
- Nashville-**Dec. 4, 2019**
- Birmingham, Ala.
- Charlotte, N.C.
- San Antonio
- San Diego
- Tampa, Fla.
- Tucson, Ariz.
- Washington, D.C.
- Vancouver, B.C.

*Please visit sitcancer.org/aci for more information.

ACI PROGRAM TAKEAWAYS

ACIs are presented by local authorities in tumor immunology and cancer immunotherapy and cover the following topics:

- Treating patients with FDA-approved immunotherapies
- Interpreting new clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines
- Identifying and managing irAEs
- Employing strategies to overcome operational and reimbursement barriers to incorporating immunotherapy into your practice
- Applying foundational knowledge for clinical implementation of SITC's Cancer Immunotherapy Guidelines
- Anticipating forthcoming immunotherapy trends/treatments/trials and how they impact your patients and practices
- Recognizing common and uncommon toxicities in immunotherapy patients and provide solutions/adjustments in treatment to address them

The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.



Postgraduate Institute
for Medicine



The 2019-2020 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, Incyte Corporation and Merck & Co., Inc. (as of July 23, 2019).

For full accreditation information and to register for these events, please visit

sitcancer.org/aci





WHY ATTEND?

- Earn CME, CPE and CNE credits and MOC points
- Attend for FREE if you are a healthcare professional, student, patient or patient advocate
- Hear from and network with local experts in tumor immunology and cancer immunotherapy

ACCREDITATION INFORMATION

AMA Credit Designation

This activity has been approved for *AMA PRA Category 1 Credit(s)*™.

Pharmacist Credit Designation

This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

Nursing Credit Designation

This activity is eligible for ANCC contact hours, see final CNE activity announcement for specific details.



Thank you to our dedicated organizers who make our ACI live programs so engaging and impactful:

CLEVELAND-SEPT. 5, 2019

Brian Rini, MD – *Cleveland Clinic Cancer Center*
Pauline Funchain, MD – *Cleveland Clinic Cancer Center*
Jung-Min Song, CNP, RN – *Cleveland Clinic Cancer Center*

CHICAGO-SEPT. 28, 2019

Derek A. Wainwright, PhD – *Northwestern University*
Jeffrey A. Sosman, MD – *Northwestern University*
Lisa Ha, RN – *Northwestern Medicine*

BOSTON-OCT. 10, 2019

David F. McDermott, MD – *Beth Israel Deaconess Medical Center*
Elizabeth Buchbinder, MD, PhD – *Dana-Farber Cancer Institute*
Virginia Seery, MSN, RN, ANP-BC – *Beth Israel Deaconess Medical Center*

BUFFALO, N.Y.-OCT. 26, 2019

Igor Puzanov, MD, MSCI, FACP – *Roswell Park Comprehensive Cancer Center*
Cheryl Raczky, PA – *Roswell Park Comprehensive Cancer Center*

SAN FRANCISCO-NOV. 4, 2019

Terence Friedlander, MD – *University of California San Francisco*
Katy K. Tsai, MD – *University of California San Francisco*
Lissa Gray, NP – *University of California San Francisco*

NASHVILLE, TENN.-DEC. 4, 2019

Anil Shanker, PhD – *Meharry Medical College School of Medicine*
Suzanne Jones, PharmD – *Sarah Cannon*
Jeffrey C. Rathmell, PhD – *Vanderbilt University School of Medicine*

The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.



Postgraduate Institute
for Medicine



The 2019-2020 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, Incyte Corporation and Merck & Co., Inc. (as of July 23, 2019).

For full accreditation information and to register for these events, please visit

sitcancer.org/aci